15 December 2024NewsAmericasChristopher Sweeney Executive Director Acuitas Therapeutics, Alison Maddeford Director Litigation & Risk Management Thermo Fisher Scientific, Daniel Yarbrough Head of Intellectual Property Element Biosciences, Madhuri Roy Partner Cooley

WATCH: The challenge of protecting patents and innovation - obviousness-type double patenting post In re Cellect

Speakers from Acuitas Therapeutics, Thermo Fisher Scientific, Element Biosciences, and Cooley examine the risks and implications of obviousness-type double patenting and offer guidance for mitigating its impact on innovation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
21 January 2026   The court’s review of a high-profile dispute could offer clarity on a grey area for pharma companies and generic drug makers, but also prompt fresh questions.
Americas
19 January 2026   An Israeli medical device company’s lawsuit claims Edwards knowingly infringed its heart-valve patent, raising new risks as the giant pursues growth beyond its core market.
Americas
15 January 2026   The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.